The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease (CKD). We performed an analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) t...

Full description

Bibliographic Details
Published in:	Kidney International Reports
Main Authors:	Michele Provenzano, Niels Jongs, Priya Vart, Bergur V. Stefánsson, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Subjects:	chronic kidney disease DAPA-CKD dapagliflozin hyperkalemia mineralocorticoid receptor antagonists sodium–glucose cotransporter-2 inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S246802492101603X

Similar Items

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
by: Minara S. Shamkhalova, et al.
Published: (2022-11-01)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020-02-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

Diagnostic Predicament of Persistent Electrolyte Imbalance in a Neonate, Pseudohypoaldosteronism (PHA)
by: Ahsan Ahmad Ghauri, et al.
Published: (2023-07-01)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
by: Memory MUKANGWA, et al.
Published: (2019-12-01)

Report from the 5th cardiovascular outcome trial (CVOT) summit
by: Oliver Schnell, et al.
Published: (2020-04-01)

Pseudohypoaldosteronism Type 1 with a Novel Mutation in the Gene: A Case Report
by: Young Min Kim, et al.
Published: (2020-04-01)

Effects of Dapagliflozin in Patients with Membranous Nephropathy
by: Glenn M. Chertow, et al.
Published: (2024-06-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

Results of the DAPA-CKD trial and their impact on clinical practice
by: O.V. Bilchenko
Published: (2023-06-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Dapagliflozin attenuates atrial fibrosis via the HMGB1/RAGE pathway in atrial fibrillation rats
by: Tan Zhenni, et al.
Published: (2025-09-01)

WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL
by: G.M. Chertow, et al.
Published: (2021-04-01)

Therapeutic Potential of Mineralocorticoid Receptors in Skeletal Muscle Aging
by: Ricardo Aparecido Baptista Nucci, et al.
Published: (2025-07-01)

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
by: Yue Zhang, et al.
Published: (2025-09-01)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
by: M. Arow, et al.
Published: (2020-01-01)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
by: Schwartz SS, et al.
Published: (2016-03-01)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
by: Jeovanna Lowe, et al.
Published: (2025-12-01)

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics
by: Julia J. Liang, et al.
Published: (2025-03-01)

case of liquorice-infused marijuana causing syndrome of apparent mineralocorticoid excess
by: Asnia Latif, et al.
Published: (2023-08-01)

Research progress on the effects of mineralocorticoid receptor on cardiovascular diseases
by: MA Qian-yu, PENG Shi, ZHANG Zhao-yuan, ZHANG Dan, ZHANG Jin
Published: (2022-08-01)

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex
by: Naoto Kuyama, et al.
Published: (2024-09-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice
by: Stefanny M. Figueroa, et al.
Published: (2023-04-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
by: Irina N. Bobkova
Published: (2023-11-01)

Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data
by: Zh. D. Kobalava, et al.
Published: (2020-06-01)

Sodium-glucose cotransporter-2 inhibitor, dapagliflozin, reverses depressive-like behavior in a mouse model of post-traumatic stress disorder
by: Haneen Amawi, et al.
Published: (2025-08-01)

Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolism
by: Mohammad Mohabbulla Mohib, et al.
Published: (2024-12-01)

Blockade of mineralocorticoid receptor by low-dose spironolactone rescues hypothalamic-ovarian dysfunction in PCOS experimental rat model
by: Stephanie E. Areleogbe, et al.
Published: (2022-12-01)

Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
by: Stefania Gorini, et al.
Published: (2019-08-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Apparent mineralocorticoid excess - A rare cause of endocrine hypertension
by: Sonali Verma, et al.
Published: (2022-01-01)

Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy
by: Riccardo Pofi, et al.
Published: (2023-08-01)

Overexpression of mineralocorticoid receptors does not affect memory and anxiety-like behavior in female mice
by: Sofia eKanatsou, et al.
Published: (2015-07-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity
by: A. A. Avagimyan, et al.
Published: (2023-11-01)